Co-development of diagnostic vectors to support targeted therapies and theranostics: Essential tools in personalized cancer therapy

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Nicolaides, Nicholas C ^a   O'Shannessy, Daniel J ^a   Albone, Earl ^a   Grasso, Luigi ^a  

^a Morphotek Inc   (United States)

Author keywords

CDx; Co development; Companion diagnostics; Nanoparticles; Naturally occurring proteins; Personalized medicine; Theranostics; TM601

Indexed keywords

AFATINIB; ANASTROZOLE; ARSENIC TRIOXIDE; B RAF KINASE; BOSUTINIB; BRENTUXIMAB VEDOTIN; BUSULFAN; CAPECITABINE; CELL SURFACE PROTEIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DABRAFENIB; DASATINIB; DEFERASIROX; DENILEUKIN DIFTITOX; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; K RAS PROTEIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; TOSITUMOMAB I 131; TRAMETINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CELL LINEAGE; COLORECTAL CANCER; DNA REPLICATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC TRANSFORMATION; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROTUBULE ASSEMBLY; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; REVIEW; RNA SPLICING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VALIDATION PROCESS;

EID: 84904687739     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00141     Document Type: Review

References (57)

1. Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther (2010) 88:765-773. doi: 10.1038/clpt.2010.230
2. Nicolaides NC, Sass PM, Grasso L. Advances in targeted therapeutic agents. Expert Opin Drug Discov (2010) 5:1123-40. doi:10.1517/17460441.2010.521496
3. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 12:572-8. doi:10.1038/nrc3299
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 355:2408-17. doi:10.1056/NEJMoa062867
5. Mologni L. Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs (2012) 21:985-94. doi:10.1517/13543784.2012.690031
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364:2507-16. doi:10.1056/NEJMoa1103782
7. Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med (2013) 3:288-305. doi:10.3390/jpm3040288
8. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Hart AA, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415:530-6. doi:10.1038/415530a
9. National Comprehensive Cancer Network. Guidelines for Patients: Breast Cancer (Version 2.2011). Available from: http://www.nccn.org/patients/guidelines/cancers.aspx#breast
10. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 24:3726-34. doi:10.1200/JCO.2005.04.7985
11. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, et al. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One (2013) 8:e60778. doi:10.1371/journal.pone.0060778
12. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monoghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol (2009) 27:18s.
13. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 261:212-5. doi:10.1126/science.8327892
14. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 26:925-32. doi:10.1038/nbt.1480
15. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol (2002) 20:2453-63. doi:10.1200/JCO.2002.11.017
16. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 19:3918-28.
17. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2011) 29:398-405. doi:10.1200/JCO.2010.29.5865
18. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy (2011) 3:475-85. doi:10.2217/imt.11.15
19. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies (2013) 2:113-29. doi:10.3390/antib2010113
20. Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMMI Res (2011) 1:1-12. doi:10.1186/2191-219X-1-18
21. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res (2001) 61:4750-5.
22. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 501:338-45. doi:10.1038/nature12625
23. FDA Press Release. FDA Allows Marketing of Four "Next Generation" Gene Sequencing devices: Two Devices Aid in Screening and Diagnosis of Cystic Fibrosis (2013). Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm375742.html
24. Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother (1997) 45:128-30. doi:10.1007/s002620050414
25. Jain M, Chauhan SC, Singh AP, Venkatraman G, Colcher D, Batra SK. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 65:7840-6.
26. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol (2002) 13:603-8. doi:10.1016/S0958-1669(02)00352-X
27. Kavak E, Ünlü M, Nistér M, Koman A. Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation. Nucleic Acids Res (2010) 20:7008-21. doi:10.1093/nar/gkq574
28. Cottu PH, Asselah J, Lae M, Pierga JY, Diéras V, Mignot L, et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 19:595-7. doi:10.1093/annonc/mdn021
29. Olivera BM, Rivier J, Clark C, Ramilo CA, Corpuz GP, Ramilo CA, et al. Diversity of Conus neuropeptides. Science (1990) 249:257-63. doi:10.1126/science.2165278
30. Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv (2005) 2:43-51. doi:10.1517/17425247.2.1.43
31. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov (2010) 9:615-27. doi:10.1038/nrd2591
32. Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol (2006) 24:942-6. doi:10.1038/nbt0806-942
33. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 29:3085-96. doi:10.1200/JCO.2010.33.2312
34. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Aptamer theragnostic. Biomaterials (2012) 33:207-17. doi:10.1016/j.biomaterials.2011.09.023
35. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 64:7668-72. doi:10.1158/0008-5472.CAN-04-2550
36. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol (2009) 86:151-64. doi:10.1016/j.yexmp.2009.01.004
37. De Luca V, Salim V, Atsumi SM, Yu F. Mining the biodiversity of plants: a revolution in the making. Science (2012) 336:1658-61. doi:10.1126/science.1217410
38. Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev Proteomics (2009) 6(221-224):2009. doi:10.1586/epr.09.45
39. Gupta VR, Wilson BA, Blanke SR. Sphingomyelin is important for the cellular entry and intracellular localization of Helicobacter pylori. Cell Microbiol (2010) 12:1517-33. doi:10.1111/j.1462-5822.2010.01487.x
40. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 446:801-5. doi:10.1038/nature05654
41. Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 121:678-84. doi:10.1053/gast.2001.27124
42. Nascimento FD, Hayashi MAF, Kerkis A, Oliveira V, Oliveira EB, Rádis-Baptista G, et al. Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. J Biol Chem (2007) 282:21349-60. doi:10.1074/jbc.M604876200
43. DeBin JA, Maggio JE, Strichartz GR. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol (1993) 264:C361-9.
44. Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, et al. Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem (2010) 285:4366-74. doi:10.1074/jbc.M109.066092
45. Neuberger T, Schöpf B, Hofmann H, Hofmann M, von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater (2005) 293:483-96. doi:10.1016/j.jmmm.2005.01.064
46. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia (2002) 39:162-73. doi:10.1002/glia.10083
47. Kievit FM, Veiseh O, Fang C, Bhattarai N, Lee D, Ellenbogen RD, et al. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. J Drug Tar (2012) 20:67-75. doi:10.1021/nn1008512
48. Lima e Silva R, Shen J, Gong YY, Seidel CP, Hackett SF, Kesavan K, et al. Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol (2010) 225:855-64. doi:10.1002/jcp.22296
49. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv (2007) 4:175-86. doi:10.1517/17425247.4.2.175
50. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 67:6882-8. doi:10.1158/0008-5472.CAN-06-3948
51. Gribbin TE, Senzer N, Raizer JJ, Shen S, Nabors LB, Wiranowska M, et al. A phase I evaluation of intravenous (IV) 131I-chlorotoxin delivery to solid peripheral and intracranial tumors. J Clin Oncol (2009) 27:e14507.
52. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 39:S103-12. doi:10.1007/s00259-011-2039-y
53. Seldin DW. Techniques for using BEXXAR for the treatment of non-Hodgkin's lymphoma. J Nucl Med Technol (2002) 30:109-14.
54. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 7:6-14.
55. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, et al. Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 2:1227-43.
56. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 31:4400-6. doi:10.1200/JCO.2013.49.7685
57. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 13:372-7. doi:10.1038/nm1486